Syndax Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Welcome, everyone, to the Wednesday morning of the 41st Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at J.P. Morgan. I'm joined by my colleagues, Malcolm Kuno and Priyanka Grover. Our next presenting company is Syndax and presenting on the behalf of the company, we have CEO, Michael Metzger.
Thank you, Anupam. I want to first start off by saying this is our first time presenting as a company at JPMorgan. So we're thrilled to be here. Appreciate the opportunity to do so. Also appreciate the initiation report from Anupam to start '23. It was a great way to begin the year.
So with that, this is our forward-looking statements. Of course, I'll be making forward-looking statements today. This is posted on our website. I encourage you to take a look at it. It's also in our presentation.
So 2023 is shaping up to be a, what I would call, a very
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |